Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

Optimized tumor cryptic peptides: the basis for universal neo-antigen-like tumor vaccines.

Menez-Jamet J, Gallou C, Rougeot A, Kosmatopoulos K.

Ann Transl Med. 2016 Jul;4(14):266. doi: 10.21037/atm.2016.05.15. Review.

2.

A general strategy to optimize immunogenicity of HLA-B*0702 restricted cryptic peptides from tumor associated antigens: Design of universal neo-antigen like tumor vaccines for HLA-B*0702 positive patients.

Gallou C, Rougeot A, Graff-Dubois S, Kosmatopoulos K, Menez-Jamet J.

Oncotarget. 2016 Sep 13;7(37):59417-59428. doi: 10.18632/oncotarget.11086.

3.

Hypoxic stress: obstacles and opportunities for innovative immunotherapy of cancer.

Chouaib S, Noman MZ, Kosmatopoulos K, Curran MA.

Oncogene. 2017 Jan 26;36(4):439-445. doi: 10.1038/onc.2016.225. Epub 2016 Jun 27. Review.

4.

A multicenter randomized phase IIb efficacy study of Vx-001, a peptide-based cancer vaccine as maintenance treatment in advanced non-small-cell lung cancer: treatment rationale and protocol dynamics.

Georgoulias V, Douillard JY, Khayat D, Manegold C, Rosell R, Rossi A, Menez-Jamet J, Iché M, Kosmatopoulos K, Gridelli C.

Clin Lung Cancer. 2013 Jul;14(4):461-5. doi: 10.1016/j.cllc.2013.02.001. Epub 2013 May 4.

PMID:
23647738
5.

Sequential administration of the native TERT572 cryptic peptide enhances the immune response initiated by its optimized variant TERT(572Y) in cancer patients.

Vetsika EK, Papadimitraki E, Aggouraki D, Konsolakis G, Mela ME, Kotsakis A, Christou S, Patramani S, Alefantinou M, Kaskara A, Christophyllakis C, Kosmatopoulos K, Georgoulias V, Mavroudis D.

J Immunother. 2011 Nov-Dec;34(9):641-50. doi: 10.1097/CJI.0b013e31823284a6.

PMID:
21989412
6.

Clinical outcome of patients with various advanced cancer types vaccinated with an optimized cryptic human telomerase reverse transcriptase (TERT) peptide: results of an expanded phase II study.

Kotsakis A, Vetsika EK, Christou S, Hatzidaki D, Vardakis N, Aggouraki D, Konsolakis G, Georgoulias V, Christophyllakis Ch, Cordopatis P, Kosmatopoulos K, Mavroudis D.

Ann Oncol. 2012 Feb;23(2):442-9. doi: 10.1093/annonc/mdr396. Epub 2011 Aug 25.

PMID:
21873272
7.

Immunological responses in cancer patients after vaccination with the therapeutic telomerase-specific vaccine Vx-001.

Vetsika EK, Konsolakis G, Aggouraki D, Kotsakis A, Papadimitraki E, Christou S, Menez-Jamet J, Kosmatopoulos K, Georgoulias V, Mavroudis D.

Cancer Immunol Immunother. 2012 Feb;61(2):157-168. doi: 10.1007/s00262-011-1093-4. Epub 2011 Aug 20.

PMID:
21858533
8.

Development of optimized cryptic peptides for immunotherapy.

Menez-Jamet J, Kosmatopoulos K.

IDrugs. 2009 Feb;12(2):98-102. Review.

PMID:
19204883
9.

CD8 T cell responses to myelin oligodendrocyte glycoprotein-derived peptides in humanized HLA-A*0201-transgenic mice.

Mars LT, Bauer J, Gross DA, Bucciarelli F, Firat H, Hudrisier D, Lemonnier F, Kosmatopoulos K, Liblau RS.

J Immunol. 2007 Oct 15;179(8):5090-8.

10.

A polyepitope DNA vaccine targeted to Her-2/ErbB-2 elicits a broad range of human and murine CTL effectors to protect against tumor challenge.

Scardino A, Alimandi M, Correale P, Smith SG, Bei R, Firat H, Cusi MG, Faure O, Graf-Dubois S, Cencioni G, Marrocco J, Chouaib S, Lemonnier FA, Jackson AM, Kosmatopoulos K.

Cancer Res. 2007 Jul 15;67(14):7028-36.

11.

Vaccination of patients with advanced non-small-cell lung cancer with an optimized cryptic human telomerase reverse transcriptase peptide.

Bolonaki I, Kotsakis A, Papadimitraki E, Aggouraki D, Konsolakis G, Vagia A, Christophylakis C, Nikoloudi I, Magganas E, Galanis A, Cordopatis P, Kosmatopoulos K, Georgoulias V, Mavroudis D.

J Clin Oncol. 2007 Jul 1;25(19):2727-34.

PMID:
17602077
12.

Induction of multiple CD8+ T cell responses against the inducible Hsp70 employing an Hsp70 oligoepitope peptide.

Faure O, Graff-Dubois S, Alves PM, Cornet S, Duffour MT, Scardino A, Gross DA, Miconnet I, Salcedo M, Chouaib S, Lemonnier FA, Abastado JP, Kosmatopoulos K.

Oncol Rep. 2007 Mar;17(3):679-85.

PMID:
17273751
13.

A phase I study of the optimized cryptic peptide TERT(572y) in patients with advanced malignancies.

Mavroudis D, Bolonakis I, Cornet S, Myllaki G, Kanellou P, Kotsakis A, Galanis A, Nikoloudi I, Spyropoulou M, Menez J, Miconnet I, Niniraki M, Cordopatis P, Kosmatopoulos K, Georgoulias V.

Oncology. 2006;70(4):306-14. Epub 2006 Oct 12.

PMID:
17047402
14.

STEAP, a prostate tumor antigen, is a target of human CD8+ T cells.

Alves PM, Faure O, Graff-Dubois S, Cornet S, Bolonakis I, Gross DA, Miconnet I, Chouaib S, Fizazi K, Soria JC, Lemonnier FA, Kosmatopoulos K.

Cancer Immunol Immunother. 2006 Dec;55(12):1515-23. Epub 2006 Apr 19.

PMID:
16622681
15.

Optimal organization of a polypeptide-based candidate cancer vaccine composed of cryptic tumor peptides with enhanced immunogenicity.

Cornet S, Miconnet I, Menez J, Lemonnier F, Kosmatopoulos K.

Vaccine. 2006 Mar 15;24(12):2102-9. Epub 2005 Nov 28.

PMID:
16455166
16.

CpG oligodeoxynucleotides activate dendritic cells in vivo and induce a functional and protective vaccine immunity against a TERT derived modified cryptic MHC class I-restricted epitope.

Cornet S, Menez-Jamet J, Lemonnier F, Kosmatopoulos K, Miconnet I.

Vaccine. 2006 Mar 10;24(11):1880-8. Epub 2005 Oct 28.

PMID:
16300869
17.

pH-triggered microparticles for peptide vaccination.

Haining WN, Anderson DG, Little SR, von Bergwelt-Baildon MS, Cardoso AA, Alves P, Kosmatopoulos K, Nadler LM, Langer R, Kohane DS.

J Immunol. 2004 Aug 15;173(4):2578-85. Erratum in: J Immunol. 2004 Nov 15;173(10):following 6489. von Berwelt-Baildon, MS [corrected to von Bergwelt-Baildon, MS].

18.

High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy.

Gross DA, Graff-Dubois S, Opolon P, Cornet S, Alves P, Bennaceur-Griscelli A, Faure O, Guillaume P, Firat H, Chouaib S, Lemonnier FA, Davoust J, Miconnet I, Vonderheide RH, Kosmatopoulos K.

J Clin Invest. 2004 Feb;113(3):425-33.

19.

Inducible Hsp70 as target of anticancer immunotherapy: Identification of HLA-A*0201-restricted epitopes.

Faure O, Graff-Dubois S, Bretaudeau L, Derré L, Gross DA, Alves PM, Cornet S, Duffour MT, Chouaib S, Miconnet I, Grégoire M, Jotereau F, Lemonnier FA, Abastado JP, Kosmatopoulos K.

Int J Cancer. 2004 Mar 1;108(6):863-70.

20.

EphA2 as target of anticancer immunotherapy: identification of HLA-A*0201-restricted epitopes.

Alves PM, Faure O, Graff-Dubois S, Gross DA, Cornet S, Chouaib S, Miconnet I, Lemonnier FA, Kosmatopoulos K.

Cancer Res. 2003 Dec 1;63(23):8476-80.

21.

Peptides derived from the onconeural HuD protein can elicit cytotoxic responses in HHD mouse and human.

Plonquet A, Garcia-Pons F, Fernandez E, Philippe C, Marquet J, Rouard H, Delfau-Larue MH, Kosmatopoulos K, Lemonnier F, Farcet JP, Gherardi RK, Langlade-Demoyen P.

J Neuroimmunol. 2003 Sep;142(1-2):93-100.

PMID:
14512168
22.

In vivo study of the GC90/IRIV vaccine for immune response and autoimmunity into a novel humanised transgenic mouse.

Scardino A, Correale P, Firat H, Pellegrini M, Kosmatopoulos K, Opolon P, Alves P, Zurbriggen R, Glück R, Lemonnier FA, Francini G, Cusi MG.

Br J Cancer. 2003 Jul 7;89(1):199-205.

23.

Anchoring cytokines to tumor cells for the preparation of anticancer vaccines without gene transfection in mice.

Nizard P, Gross DA, Babon A, Chenal A, Beaumelle B, Kosmatopoulos K, Gillet D.

J Immunother. 2003 Jan-Feb;26(1):63-71.

PMID:
12514430
24.

High-affinity HLA-A(*)02.01 peptides from parathyroid hormone-related protein generate in vitro and in vivo antitumor CTL response without autoimmune side effects.

Francini G, Scardino A, Kosmatopoulos K, Lemonnier FA, Campoccia G, Sabatino M, Pozzessere D, Petrioli R, Lozzi L, Neri P, Fanetti G, Cusi MG, Correale P.

J Immunol. 2002 Nov 1;169(9):4840-9.

25.

Generation of CTL recognizing an HLA-A*0201-restricted epitope shared by MAGE-A1, -A2, -A3, -A4, -A6, -A10, and -A12 tumor antigens: implication in a broad-spectrum tumor immunotherapy.

Graff-Dubois S, Faure O, Gross DA, Alves P, Scardino A, Chouaib S, Lemonnier FA, Kosmatopoulos K.

J Immunol. 2002 Jul 1;169(1):575-80.

26.

HER-2/neu and hTERT cryptic epitopes as novel targets for broad spectrum tumor immunotherapy.

Scardino A, Gross DA, Alves P, Schultze JL, Graff-Dubois S, Faure O, Tourdot S, Chouaib S, Nadler LM, Lemonnier FA, Vonderheide RH, Cardoso AA, Kosmatopoulos K.

J Immunol. 2002 Jun 1;168(11):5900-6.

27.

ALK as a novel lymphoma-associated tumor antigen: identification of 2 HLA-A2.1-restricted CD8+ T-cell epitopes.

Passoni L, Scardino A, Bertazzoli C, Gallo B, Coluccia AM, Lemonnier FA, Kosmatopoulos K, Gambacorti-Passerini C.

Blood. 2002 Mar 15;99(6):2100-6.

PMID:
11877285
28.

Tumor-associated antigen human chorionic gonadotropin beta contains numerous antigenic determinants recognized by in vitro-induced CD8+ and CD4+ T lymphocytes.

Dangles V, Halberstam I, Scardino A, Choppin J, Wertheimer M, Richon S, Quelvennec E, Moirand R, Guillet JG, Kosmatopoulos K, Bellet D, Zeliszewski D.

Cancer Immunol Immunother. 2002 Feb;50(12):673-81. Epub 2001 Dec 12.

PMID:
11862419
29.

[Anchoring cytokines to cancer cells using diphtheria toxin: better than immunotherapy by gene transfer?].

Nizard P, Gross DA, Chenal A, Beaumelle B, Kosmatopoulos K, Gillet D.

J Soc Biol. 2001;195(3):229-34. Review. French.

PMID:
11833459
30.

Identification of HER-2/neu immunogenic epitopes presented by renal cell carcinoma and other human epithelial tumors.

Scardino A, Alves P, Gross DA, Tourdot S, Graff-Dubois S, Angevin E, Firat H, Chouaib S, Lemonnier F, Nadler LM, Cardoso AA, Kosmatopoulos K.

Eur J Immunol. 2001 Nov;31(11):3261-70.

31.

Design of a polyepitope construct for the induction of HLA-A0201-restricted HIV 1-specific CTL responses using HLA-A*0201 transgenic, H-2 class I KO mice.

Firat H, Tourdot S, Ureta-Vidal A, Scardino A, Suhrbier A, Buseyne F, Rivìere Y, Danos O, Michel ML, Kosmatopoulos K, Lemonnier FA.

Eur J Immunol. 2001 Oct;31(10):3064-74.

32.

[Technological advances in immuno-oncology: from fundamental concepts to patient immunological monitoring].

Chouaib S, Echchakir H, Angevin E, Guerra N, Kosmatopoulos K, Caignard A, Lim A, Baron V, Ferradini L, Mami-Chouaib F.

Bull Cancer. 2001 Aug;88(8):733-40. Review. French.

33.

A general strategy to enhance immunogenicity of low-affinity HLA-A2. 1-associated peptides: implication in the identification of cryptic tumor epitopes.

Tourdot S, Scardino A, Saloustrou E, Gross DA, Pascolo S, Cordopatis P, Lemonnier FA, Kosmatopoulos K.

Eur J Immunol. 2000 Dec;30(12):3411-21.

34.

Role of astrocytes in antigen presentation and naive T-cell activation.

Cornet A, Bettelli E, Oukka M, Cambouris C, Avellana-Adalid V, Kosmatopoulos K, Liblau RS.

J Neuroimmunol. 2000 Jul 1;106(1-2):69-77.

PMID:
10814784
35.

H-2 class I knockout, HLA-A2.1-transgenic mice: a versatile animal model for preclinical evaluation of antitumor immunotherapeutic strategies.

Firat H, Garcia-Pons F, Tourdot S, Pascolo S, Scardino A, Garcia Z, Michel ML, Jack RW, Jung G, Kosmatopoulos K, Mateo L, Suhrbier A, Lemonnier FA, Langlade-Demoyen P.

Eur J Immunol. 1999 Oct;29(10):3112-21.

36.

Major histocompatibility complex class I presentation of exogenously acquired minor alloantigens initiates skin allograft rejection.

Oukka M, Galou M, Belkaid Y, Tricotet V, Riche N, Reynes M, Kosmatopoulos K.

Eur J Immunol. 1997 Dec;27(12):3499-506.

PMID:
9464840
37.

Chimeric peptides: a new approach to enhancing the immunogenicity of peptides with low MHC class I affinity: application in antiviral vaccination.

Tourdot S, Oukka M, Manuguerra JC, Magafa V, Vergnon I, Riché N, Bruley-Rosset M, Cordopatis P, Kosmatopoulos K.

J Immunol. 1997 Sep 1;159(5):2391-8.

PMID:
9278330
38.

Selectivity of the major histocompatibility complex class II presentation pathway of cortical thymic epithelial cell lines.

Oukka M, Andre P, Turmel P, Besnard N, Angevin V, Karlsson L, Trans PL, Charron D, Bihain B, Kosmatopoulos K, Lotteau V.

Eur J Immunol. 1997 Apr;27(4):855-9.

PMID:
9130635
39.

Protection against lethal viral infection by vaccination with nonimmunodominant peptides.

Oukka M, Manuguerra JC, Livaditis N, Tourdot S, Riche N, Vergnon I, Cordopatis P, Kosmatopoulos K.

J Immunol. 1996 Oct 1;157(7):3039-45.

PMID:
8816413
40.

CD4 T cell tolerance to nuclear proteins induced by medullary thymic epithelium.

Oukka M, Colucci-Guyon E, Tran PL, Cohen-Tannoudji M, Babinet C, Lotteau V, Kosmatopoulos K.

Immunity. 1996 Jun;4(6):545-53.

41.

Medullary thymic epithelial cells induce tolerance to intracellular proteins.

Oukka M, Cohen-Tannoudji M, Tanaka Y, Babinet C, Kosmatopoulos K.

J Immunol. 1996 Feb 1;156(3):968-75.

PMID:
8558024
42.

The J alpha segment contributes to the affinity of V beta 6+ cells for vSAG-7 (Mls-1a) presented by I-A molecules.

Churaqui E, Oukka M, Tilloy F, Mayadoux E, Bruley-Rosset M, Kosmatopoulos K.

Immunology. 1995 Apr;84(4):609-18.

43.

Dose-dependent T cell tolerance to an immunodominant self peptide.

Cabaniols JP, Cibotti R, Kourilsky P, Kosmatopoulos K, Kanellopoulos JM.

Eur J Immunol. 1994 Aug;24(8):1743-9.

PMID:
8056033
44.

A nonimmunodominant nucleoprotein-derived peptide is presented by influenza A virus-infected H-2b cells.

Oukka M, Riché N, Kosmatopoulos K.

J Immunol. 1994 May 15;152(10):4843-51.

PMID:
8176207
45.

Tolerance to a self-protein involves its immunodominant but does not involve its subdominant determinants.

Cibotti R, Kanellopoulos JM, Cabaniols JP, Halle-Panenko O, Kosmatopoulos K, Sercarz E, Kourilsky P.

Proc Natl Acad Sci U S A. 1992 Jan 1;89(1):416-20.

46.

Mechanism of hybrid resistance. The role of a natural antibody in parental bone marrow cell rejection.

Cabaniols JP, Bolonakis-Tsilivakos I, Cibotti R, Churaqui E, Duc HT, Halle-Pannenko O, Kosmatopoulos K.

J Immunol. 1991 Feb 1;146(3):860-4.

PMID:
1988500
47.

Specific inhibition of hybrid resistance in F1 hybrid mice pretreated with parent-strain spleen cells. III. Study of the mechanism.

Cibotti R, Churaqui E, Bolonakis-Tsilivakos I, Scott-Algara D, Hallepannenko O, Kosmatopoulos K.

J Immunol. 1989 Dec 1;143(11):3484-91.

PMID:
2573634
48.
50.

Suppression of the in vitro parent antihybrid reaction by spleen cells from F1 hybrids pretreated with spleen cells from the opposite parent strain.

Kosmatopoulos K, Scott-Algara D, Cabannes J, Orbach Arbouys S.

Transplantation. 1987 Dec;44(6):823-31.

PMID:
2962346

Supplemental Content

Loading ...
Support Center